Adrian M. Di Bisceglie
Hepatology · 2011–2012
A researcher in the Science corpus: 2 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Hepatology — 78 citations into it
Whom Adrian M. Di Bisceglie trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from Adrian M. Di Bisceglie's perspective
Ordered by how strongly the researchers Adrian M. Di Bisceglie trusts endorse each paper. Same corpus, a different order for every researcher.
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
- Hepatocellular carcinoma in cirrhosis: incidence and risk factors. (Gastroenterology)
- Portal Vein Embolization Before Right Hepatectomy: Prospective Clinical Trial (Annals of Surgery)
- Novel advancements in the management of hepatocellular carcinoma in 2008. (Journal of Hepatology)
- INCIDENCE OF HEPATOCELLULAR CARCINOMA AND ASSOCIATED RISK FACTORS IN HEPATITIS C-RELATED ADVANCED LIVER DISEASE (Gastroenterology)
- The natural history of compensated cirrhosis due to hepatitis C virus: A 17‐year cohort study of 214 patients (Hepatology)
- Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. (Journal of Clinical Oncology)
- Noninvasive assessment of liver fibrosis (Hepatology)
- Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. (Journal of Hepatology)
- Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. (Journal of the American College of Surgeons)
Their papers
- EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. (2012) — 3,548 citations
- Telaprevir for previously untreated chronic hepatitis C virus infection. (2011) — 2,552 citations